MYC基因作为胚胎性肿瘤的治疗靶点：潜力与挑战

Title:MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges

Volume: 16 Issue: 1

Author(s): Tarek Shalaby and Michael A. Grotzer

Affiliation:

关键词: 胚胎性肿瘤、髓母细胞瘤、MYC基因、神经母细胞瘤，儿科癌症

摘要: The MYC family plays essential roles during brain development and their oncogenic deregulation is implicated in the formation of embryonal neural tumors such as medulloblastomas (MB) and neuroblastoma (NB). Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis. Not surprisingly MYC has emerged as an attractive target for pediatric neural cancer therapy. However despite three decades of intensive research in MYC biology and an impressive number of 30,000 publications, inhibition of MYC as therapeutic strategy remains an elusive goal in cancer medicine. This review discusses the potential and challenges of targeting the oncogenic effects of MYC as therapeutic strategy for MYC over-expressing embryonal neural tumors where current therapies are inadequate.

Cite this article as:

Tarek Shalaby and Michael A. Grotzer , MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges, Current Cancer Drug Targets 2016; 16 (1) . https://dx.doi.org/10.2174/1568009615666150916092745